Painful Diabetic Peripheral Neuropathy Study of Chinese OutPatiEnts (PDN-SCOPE): protocol for a multicentre cross-sectional registry study of clinical characteristics and treatment in China

Yuanjin Zhang, Nan Li, Yiming Zhao, Dongsheng Fan, Yuanjin Zhang, Nan Li, Yiming Zhao, Dongsheng Fan

Abstract

Introduction: Painful diabetic peripheral neuropathy (PDN) is a growing public health problem in China. Despite recent progress in treatment, there has been no nationwide study evaluating current medical practices and compliance with treatment guidelines. The primary aims of this study are to investigate the clinical characteristics and treatment practices for PDN and associated anxiety and depression in China.

Methods and analysis: Painful Diabetic Peripheral Neuropathy Study of Chinese OutPatiEnts is a cross-sectional, multicentre registry study with a target sample size of approximately 1500 people experiencing PDN. People with PDN will be treated according to current guidelines and local practices. The demographics, medical histories, Visual Analogue Scale pain scores, Patient Health Questionnaire-9 results, Generalised Anxiety Disorder-7 scores and therapies will be recorded to evaluate clinical characteristics of PDN and current treatment practices for pain, anxiety and depression.

Ethics and dissemination: Ethical approval has been obtained from the Peking University Third Hospital Medical Science Research Ethics Committee (2018-182).The results of this study will be disseminated through peer-reviewed publications and scientific presentations.

Trial registration number: NCT03520608.

Keywords: clinical characteristics; outpatient; painful diabetic peripheral neuropathy; registry; treatment.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, et al. . The global burden of diabetic foot disease. Lancet 2005;366:1719–24. 10.1016/S0140-6736(05)67698-2
    1. Callaghan BC, Cheng HT, Stables CL, et al. . Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012;11:521–34. 10.1016/S1474-4422(12)70065-0
    1. Sadosky A, Schaefer C, Mann R, et al. . Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes 2013;6:79–92. 10.2147/DMSO.S37415
    1. Ziegler D, Rathmann W, Meisinger C, et al. . Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain 2009;13:582–7. 10.1016/j.ejpain.2008.07.007
    1. Van Acker K, Bouhassira D, De Bacquer D, et al. . Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206–13. 10.1016/j.diabet.2008.11.004
    1. Erbas T, Ertas M, Yucel A, et al. . Prevalence of peripheral neuropathy and painful peripheral neuropathy in Turkish diabetic patients. J Clin Neurophysiol 2011;28:51–5. 10.1097/WNP.0b013e3182051334
    1. Abbott CA, Malik RA, van Ross ER, et al. . Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220–4. 10.2337/dc11-1108
    1. Kim SS, Won JC, Kwon HS, et al. . Prevalence and clinical implications of painful diabetic peripheral neuropathy in type 2 diabetes: results from a nationwide hospital-based study of diabetic neuropathy in Korea. Diabetes Res Clin Pract 2014;103:522–9. 10.1016/j.diabres.2013.12.003
    1. Alleman CJ, Westerhout KY, Hensen M, et al. . Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: a review of the literature. Diabetes Res Clin Pract 2015;109:215–25. 10.1016/j.diabres.2015.04.031
    1. Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLoS One 2013;8:e74195 10.1371/journal.pone.0074195
    1. Malik RA, Aldinc E, Chan SP, et al. . Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia: Results from Patient and Physician Surveys. Adv Ther 2017;34:1426–37. 10.1007/s12325-017-0536-5
    1. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68:1178–82. 10.1212/01.wnl.0000259085.61898.9e
    1. Tesfaye S, Vileikyte L, Rayman G, et al. . Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev 2011;27:629–38. 10.1002/dmrr.1225
    1. D’Amato C, Morganti R, Greco C, et al. . Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. Diab Vasc Dis Res 2016;13:418–28. 10.1177/1479164116653240
    1. Attal N, Cruccu G, Baron R, et al. . EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113–88. 10.1111/j.1468-1331.2010.02999.x
    1. Brieler JA, Lustman PJ, Scherrer JF, et al. . Antidepressant medication use and glycaemic control in co-morbid type 2 diabetes and depression. Fam Pract 2016;33:30–6. 10.1093/fampra/cmv100
    1. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. . American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015;21(Suppl 1):1–87. 10.4158/EP15672.GLSUPPL
    1. O’Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27:95–112. 10.2165/00019053-200927020-00002
    1. Centre for Clinical Practice at NICE (UK). Neuropathic Pain: The Pharmacological Management of Neuropathic Pain in Adults in Non-specialist Settings. London: National Institute for Health and Care Excellence: Clinical Guidelines, 2013.
    1. Iyer S, Tanenberg RJ. Pharmacologic management of diabetic peripheral neuropathic pain. Expert Opin Pharmacother 2013;14:1765–75. 10.1517/14656566.2013.811490
    1. Hébert HL, Veluchamy A, Torrance N, et al. . Risk factors for neuropathic pain in diabetes mellitus. Pain 2017;158:560–8. 10.1097/j.pain.0000000000000785
    1. Bouhassira D, Attal N, Alchaar H, et al. . Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29–36. 10.1016/j.pain.2004.12.010
    1. Perez C, Galvez R, Huelbes S, et al. . Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes 2007;5:66 10.1186/1477-7525-5-66
    1. Chatila N, Pereira B, Maarrawi J, et al. . Validation of a New Arabic Version of the Neuropathic Pain Diagnostic Questionnaire (DN4). Pain Pract 2017;17:78–87. 10.1111/papr.12419
    1. Kim HJ, Park JH, Bouhassira D, et al. . Validation of the Korean Version of the DN4 Diagnostic Questionnaire for Neuropathic Pain in Patients with Lumbar or Lumbar-Radicular Pain. Yonsei Med J 2016;57:449–54. 10.3349/ymj.2016.57.2.449
    1. Sykioti P, Zis P, Vadalouca A, et al. . Validation of the Greek Version of the DN4 Diagnostic Questionnaire for Neuropathic Pain. Pain Pract 2015;15:627–32. 10.1111/papr.12221
    1. van Seventer R, Vos C, Giezeman M, et al. . Validation of the Dutch version of the DN4 diagnostic questionnaire for neuropathic pain. Pain Pract 2013;13:390–8. 10.1111/papr.12006
    1. Madani SP, Fateh HR, Forogh B, et al. . Validity and reliability of the persian (Farsi) version of the DN4 (Douleur Neuropathique 4 Questions) questionnaire for differential diagnosis of neuropathic from non-neuropathic pains. Pain Pract 2014;14:427–36. 10.1111/papr.12088
    1. Santos JG, Brito JO, de Andrade DC, et al. . Translation to Portuguese and validation of the Douleur Neuropathique 4 questionnaire. J Pain 2010;11:484–90. 10.1016/j.jpain.2009.09.014
    1. Spallone V, Morganti R, D’Amato C, et al. . Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med 2012;29:578–85. 10.1111/j.1464-5491.2011.03500.x
    1. Gould D, et al. . Visual Analogue Scale. Journal of Clinical Nursing;10:697–706.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–13.
    1. Syed T. PHQ-9. British Journal of General Practice 2013;63:127.2–127. 10.3399/bjgp13X664171
    1. Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. Gen Hosp Psychiatry 2015;37:67–75. 10.1016/j.genhosppsych.2014.09.009
    1. Spitzer RL, Kroenke K, Williams JB, et al. . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–7. 10.1001/archinte.166.10.1092

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa